When: Price pulls back to $87–88 zone (10 EMA / 200 SMA / Bollinger middle confluence)

Then: Deploy reserved 50% capital

When: Close above $93 on >10M volume

Then: Fully deploy reserved capital

REDUCE first tranche to 25% at 90.68; reserve 75% for 87-88 zone; adjust stop to 85.50; await CPI print and technical confirmation

• MDT crossed above 200 SMA at 88.57 but this is a start of a hypothesis, not a conclusion—reclaim levels historically get retested in fragile macro regimes
• RSI climbed from 46 to 70 in four weeks, a first print at fresh local highs with simultaneous upper Bollinger band tag suggests 1-3 day cooldown is higher probability
• 5.46 million shares volume on breakout after 24% ten-week run is historically a warning flag, not confirmation of accumulation
• Forward P/E of 14x is built on 6.41 EPS vs 3.73 trailing—a 72% expected expansion; if actuals come in at 5.50, multiple expands to ~16.5x, eliminating the valuation edge
• Stock up 16% in 90 days and just hit new local recovery high—Affera/Sphere-9 catalyst is already being priced into the stock
• Aggressive 50/50 split creates 78 basis points of portfolio heat at current extended levels vs a 25% first tranche reducing that exposure by half
• Blended entry at 25/75 split targets cost basis closer to 88 than 90, improving risk-reward meaningfully
• Stop at 86 sits exactly at the 200 SMA being tested—85.50 preferred to allow breathing room through normal 1-2 day volatility spikes
• CPI print this week, 86% probability of no Fed cuts, and rising oil on Iran deal doubts create multiple binary macro events stacked against entry in next 5 trading sessions

→ vs aggressive: The 200 SMA reclaim is one data point, not a foregone conclusion—historical default is retest in fragile macro regimes, and a retest after rejection creates the exact setup that punishes early buyers at 90.68

→ vs aggressive: RSI 70 cited as overused—this was RSI climbing from 46 to 70 in four weeks for the FIRST time in the move, not a mature trend staying elevated; simultaneous upper Bollinger tag creates dual overbought confirmation

→ vs aggressive: Interpreting 5.46 million shares as exhausted supply is confirmation bias—light-volume breakouts at fresh highs after extended runs fail more frequently than they succeed; base rate favors caution

→ vs aggressive: Forward P/E of 14x assumes 72% earnings expansion from restructuring/M&A charge elimination, FX neutrality, and clean Affera/Sphere-9 ramp—consensus estimates are opinions, not guarantees, and 14x becomes ~16.5x on 5.50 actual EPS

→ vs aggressive: The 50/50 split is not disciplined hybrid sizing—it doubles portfolio heat at the worst possible technical entry point; 25/75 split respects the technical reality and improves blended cost basis without opposing the fundamental thesis

→ vs aggressive: Calling the Affera catalyst 'not priced' when the stock is up 16% in 90 days and at new local highs is timing error—the market already priced it and the tape is correcting that error at 90.68

BUY

• 200 SMA at 88.57 and price holding above this level for 2-3 weeks is needed to confirm regime shift, not a single-session reclaim
• RSI 70 after 24% rally in 10 weeks is a yellow flag, not a green light or sell signal; probability shifts toward consolidation not reversal
• Light volume on new high in 10-week uptrend = 'uncertainty', not accumulation or distribution
• 72% expected EPS expansion is sell-side consensus historically optimistic for legacy med-tech; actuals 15% below consensus would push forward P/E from 14 to 16.5
• Stop at 86.00 is preferred over 85.50 as it aligns with structural break of 200 SMA at 88.57 and avoids whipsaw on normal retests
• Conservative analyst's 25%/75% back-loaded sizing risks permanent under-allocation if stock breaks out above 93 without pulling back to 87-88
• Macro headwind (higher-for-longer, 86% no-cut probability) is actually favorable for defensive large-cap with 3.22% dividend and 0.566 beta
• Deploy 35-40% at 90.68, reserve 60-65% for 87-88 pullback, add rebalance trigger to deploy if closes above 93 on volume above 10 million shares within 2 weeks

→ vs aggressive: Single-session reclaim above 88.57 on lowest volume of rally is hypothesis, not confirmed regime shift; 'funding a thesis, not a hope' applies in reverse

→ vs conservative: 25%/75% back-loaded sizing is too rigid; if MDT breaks out to 103 without touching 88, only 25% of intended position is captured on a 14% move

→ vs aggressive: Framing 'RSI 70 as performance destruction' is bias; it's a yellow flag requiring position sizing adjustment, not a guaranteed reversal or green light

→ vs conservative: Macro headwind is overweighted; defensive large-cap with 3.22% dividend and 0.566 beta is positioned to benefit from higher-for-longer environment

→ vs conservative: 85.50 stop materially increases whipsaw risk on normal 200 SMA retest; 86.00 is cleaner structural stop at 2.57 below 200 SMA